Attenuated human cytomegalovirus and methods of use as a vaccine or vector

Structure-guided mutations at the pp150-SCP interface in HCMV, particularly the K255E mutation, create an attenuated HCMV strain suitable for vaccines and gene therapy by reducing viral replication while maintaining infectivity.

WO2026241684A1PCT designated stage Publication Date: 2026-11-19HOWARD UNIVERSITY +5
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/028442
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-16
Filing Date
2026-05-15
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Current vaccines and therapeutic protocols for human cytomegalovirus (HCMV) are lacking, and HCMV has potential as a vector for expressing genes for vaccines against other viruses or for gene therapy, necessitating the development of a non-pathogenic live HCMV strain as a safe and efficient vector.

Method used

Introduce structure-guided mutations at the pp150-SCP interface of the HCMV tegument protein using bacterial artificial chromosomes (BACs), specifically a missense mutation K255E, to attenuate viral replication without abolishing it entirely, allowing for the use as a live-attenuated HCMV vaccine or vector.

Benefits of technology

The mutation significantly attenuates viral replication, providing a candidate for a live-attenuated HCMV vaccine or vector, suitable for vaccine development and gene therapy, with minimal infectiousness.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026028442_19112026_PF_FP_ABST
    Figure US2026028442_19112026_PF_FP_ABST
Patent Text Reader

Abstract

Provided is a pp150 tegument protein of human cytomegalovirus (HCMV) containing one or more mutations that weaken association of pp150 and small capsid protein (SCP), including a missense mutation K255E. Also provided are viral particles and attenuated HCMV containing said pp150 tegument protein, constructs encoding said pp150 tegument protein, viral particles or attenuated HCMV, and vaccines containing said viral particles or attenuated HCMV. Also provided are methods of producing said constructs and vaccines, and methods of vaccination using said vaccines.
Need to check novelty before this filing date? Find Prior Art

Description

ATTENUATED HUMAN CYTOMEGALOVIRUS AND METHODS OF USE AS AVACCINE OR VECTORBACKGROUND

[0001] Human cytomegalovirus (HCMV) typically causes severe illness in three primary groups: organ transplant recipients, individuals with AIDS, and newborns with congenital infections. Currently, there are no vaccines or established therapeutic protocols for managing HCMV diseases. Therefore, there is an urgent need for innovative approaches to develop an effective HCMV vaccine. Additionally, HCMV has shown potential as a vector for expressing one or more genes to develop vaccines against other viruses or for gene therapy purposes. To achieve this, it is crucial to produce a non-pathogenic live HCMV strain that can serve as a safe and efficient vector for HCMV-related research and vaccine development efforts. Pp150 is a tegument protein of human cytomegalovirus and essential for HCMV replication.

[0002] Structural studies have shown that pp150 complexes with the major capsid proteins (MCP) and small capsid protein (SCP) during viral replication and capsid assembly. Human cytomegalovirus (HCMV) replication relies on a nucleocapsid coat of the 150kDa, subfamilyspecific tegument phosphoprotein (pp150) to regulate cytoplasmic virion maturation. While recent structural studies revealed ppl50-capsid interactions, the role of specific amino acids involved in these interactions has not been established experimentally. In this study, ppi 50 and the small capsid protein (SCP), one of pp 150’ s binding partners found atop the major capsid protein (MCP), were subjected to mutational and structural analyses. Mutations to clusters of polar or hydrophobic residues along the pp150-SCP interface abolished viral replication, with no replication detected in mutant virus-infected cells. Notably, a single point mutation at the pp150-MCP interface significantly attenuated viral replication, unlike the situation of pp150-deletion mutation, where capsids degraded outside host nuclei. These functionally significant mutations targeting pp150-capsid interactions, particularly the pp150 K255E replication-attenuated mutant, can be explored to overcome the historical challenges of developing effective antivirals and vaccines against HCMV infection.

[0003] Human cytomegalovirus (HCMV), is a ubiquitous beta-herpesvirus which exhibits typical seroprevalence of ~83% (Zuhair et al., 2019). Though innocuous in healthy adults, HCMV infection is a leading causative agent of debilitating illnesses, such as retinitis or hepatitis, amongst the immunocompromised and the immunologically naive (Manicklal et al., 2013). HCMV is also the leading viral cause of birth defects world-wide, often causing neurological disabilities such as deafness, blindness, and microcephaly (Manicklal et al., 2013). The prevalence of HCMV and the public health burden it represents motivates ongoing work to develop more effective treatments by making use of newly available structural data.

[0004] HCMV is a member of the P-herpesvirus subfamily of the Herpesviridae, and shares general morphological characteristics of viruses from the a-herpesvirus (e g., herpes simplex virus or HSV) and y-herpesvirus (e.g., Kaposi’s sarcoma-associated herpesvirus or KSHV) subfamilies. The virion has four layers: the large double-stranded DNA genome is packed tightly into the icosahedral capsid, which is coated in amorphous tegument proteins and enclosed within a lipid envelope. The HCMV capsid is composed of 955 copies of the major capsid protein (MCP) arranged into 150 hexons with 11 pentons at the icosahedral 5-fold (15) vertices. The 12th15 vertex is occupied by a unique portal vertex, through which the viral genome is translocated. 360triplex protein complexes (Tri), each composed of one Tril and two Tri2 (Tri2A & Tri2B) copies, decorate the exterior of the MCP shell, riveting neighboring MCPs together, while small capsid protein (SCP) molecules tip each MCP tower (Figure 1 A). SCP, which varies from 8kDa in HCMV and 15 kDa in KSHV, has the greatest structural and sequence variability amongst herpesviruses (Close et al., 2018; Dai et al., 2015), being dispensable among both a- and \| / -herpesviruses but not P-herpesviruses (Borst et al., 2022; Dai et al., 2013).

[0005] As a P-herpesvirus, HCMV has several features which differentiate it from members of the other two Herpesviridae subfamilies. For instance, with greater genomic density than its a-herpesvirus cousins (Bauer et al., 2013; Muller et al., 2021), the HCMV capsid is subject to internal pressures beyond the 18 atmospheres experienced by herpes simplex virus (HSV) (Brandariz-Nunez et al., 2019). Strangely, in HCMV the stabilizing capsid vertex-specific components (CVSCs) present in HSV are replaced with the 150 kDa P-herpesvirus specific tegument phosphoprotein (ppl50) (Dai and Zhou, 2018; Wang et al., 2018; Yu et al., 2017), despite HCMV CVSCs remaining at the portal vertex (Li et al., 2021; Liu et al., 2019; Sae-Ueng et al., 2014). Indeed, structural studies have found ppl50 coats the capsid exterior of mature HCMV virions, bridging the gap between triplex heterotrimers and the small capsid protein (SCP) seated atop the neighboring major capsid proteins (MCP) of pentons and hexons (Fig. 1A) (Dai et al., 2013; Li et al., 2021; Liu et al., 2019).

[0006] Ppl50 is thought to bind to nascent HCMV nucleocapsids in the nucleus and coegress to the cytoplasm, where it enhances capsid stability and regulates maturation events at the viral assembly complex (vAC) (AuCoin et al., 2006; Tandon and Mocarski, 2008; Tandon andMocarski, 2011). The capsid-bound, N-terminal region of ppl50 consists of an upper and lowerhelix bundle, with the latter standing off Tri and the former contacting a neighboring SCP (Figure 1A) (Baxter and Gibson, 2001; Dai et al., 2013; Yu et al., 2017). Near the SCP and Tri binding sites of the helix bundles are two highly conserved regions (designated as CR1 & CR2) (Baxter and Gibson, 2001; Yu et al., 2017). Peptide mimetics of CR2 were shown to inhibit capsid binding of ppl50, though the precise mechanism of inhibition remains unclear (Mitra et al., 2021). While it was observed that SCP mediates ppl50-capsid association (Dai et al., 2013; Yu et al., 2017), the interface between SCP and ppi 50 has yet to be thoroughly characterized, and it remains unclear which, if any, residues or domains are implicated in ppl50-capsid binding.SUMMARY OF THE DISCLOSURE

[0007] It was demonstrated that the interactions between pp150 and SCP are crucial for HCMV replication because BAC-directed mutation of pp150, whose SCP-interaction was abolished, failed to make viral particles in HCMV permissive cells. Using a structure-guided method, BAC-directed mutagenesis, an attenuated HCMV that contains the pp150 that has missense mutation of K255E was generated. This HCMV-K255E-ppl50 construct can still generate infectious HCMV particles, but at a significantly lower level. Therefore, it was hypothesized that this mutated HCMVK255E-ppl50 might be used as an attenuated HCMV strain for use as a live-attenuated HCMV vaccine and / or as an HCMV vector for developing vaccines against HIV or other viruses, or for purposes of gene therapy.

[0008] Bacterial artificial chromosomes (BACs) were utilized to introduce structure-guided mutations at the ppl50-SCP interface, and the impact on viral protein interactions and replication was observed. Biochemical analysis and fluorescence imaging suggest that mutations along the ppl50-SCP interface invariably produce lethal phenotypes in HCMV, which can likelybe attributed to disruption of ppl50-SCP association. Meanwhile, a mutation was identified at the ppl50-MCP interface, which significantly attenuates but does not entirely abolish viral replication. Through ultra- structural analysis, it was observed no qualitative effect on capsid assembly, genome retention, or cytoplasmic maturation events, suggesting that this mutation to the pp150-MCP interface may impact replication following egress from the cell. Also provided is the first structural evidence to show that pp150 associates with capsids within the nucleus of infected cells and preferentially binds genome-containing capsids.

[0009] The disclosure provides a pp150 tegument protein of human cytomegalovirus (HCMV) containing one or more mutations that weaken association of pp150 and small capsid protein (SCP). A mutation may be introduced by any known method.

[0010] A mutation in the pp150 tegument protein may be in the sequence of the SCP, the sequence of pp150, or both. A mutation in the pp150 tegument protein may be a missense mutation K255E.

[0011] The disclosure also provides a viral particle comprising a pp150 tegument protein of the disclosure.

[0012] The disclosure also provides an attenuated HCMV comprising a pp150 tegument protein of the disclosure.

[0013] The disclosure also provides a construct encoding a protein of the disclosure.

[0014] The disclosure also provides a construct encoding a viral particle and a construct encoding an attenuated HCMV of the disclosure.

[0015] The disclosure also provides a cell comprising a construct of the disclosure.

[0016] The disclosure also provides a vaccine comprising a protein, a viral particle or an attenuated HCMV of the disclosure. A vaccine may contain an attenuated HCMV containing pp65, gB, and 1E1. A vaccine may contain one or more adjuvants.

[0017] The disclosure also provides a vector encoding a protein, a viral particle or an attenuated HCMV of the disclosure.

[0018] The disclosure also provides a cell expressing a protein, a cell producing a viral particle, a cell producing an attenuated HCMV, and a cell expressing a vector of the disclosure.

[0019] The disclosure also provides a method for producing a protein of the disclosure by introducing a construct encoding the protein into a cell, wherein the protein is expressed, and isolating the expressed protein.

[0020] The disclosure also provides a method for producing a viral particle of the disclosure by introducing a construct encoding the viral particle into a cell, wherein the construct is produced, and isolating the produced viral particle.

[0021] The disclosure also provides a method for producing an attenuated HCMV of the disclosure by introducing a construct expressing the attenuated HCMV into a cell, wherein the attenuated HCMV is produced, and isolating the produced attenuated HCMV. The attenuated HCMV may be of any strains.

[0022] The disclosure also provides a method of vaccinating a subject against HCMV by administering to the subject a vaccine of the disclosure.

[0023] The disclosure also provides a method for inducing immunity or boosting immunity against HCMV in a subject by administering to the subject a vaccine of the disclosure.

[0024] The disclosure also provides a method for treating a subject infected with HCMV by administering to the subject in need thereof a vaccine of the disclosure.

[0025] The subject in the methods of the disclosure may be an animal, such as a mammal. The subject in the methods of the disclosure maybe a human. The human subject maybe a child or an adult. The subject may be of any gender and any age. The subject may be previously exposed to HCMV or never exposed to HCMV. The subject may be previously treated for HCMV infection or never treated for HCMV infection.BRIEF DESCRIPTION OF THE FIGURES

[0026] FIGS. 1A-1E show structure-guided mutational analysis of the pp150-SCP interface.

[0027] FIG. 1A depicts an atomic model of the HCMV capsid with pp150 coat (left). The inset (right) shows a zoomed-in view of subunits colored to emphasize different subunit interactions.

[0028] FIG. 1B shows sequence alignment of HCMV, murine CMV (MCMV), and simian CMV (SCMV) pp150 homologues between pp150 residues 240-276. (C) surface interfaces between pp150 and SCP, with mutations colored by clusters to enhance detail (left). Surfaces with Hydrophilic, neutral, and hydrophobic areas are colored in cyan, white, and gold, respectively (middle), while positive, neutral, and negative electrostatic potentials are shown in blue, white, and red, respectively (right).

[0029] FIG. ID shows representative fluorescence microscopy images of cells transfected with SCP mutant BACs, 1 (top) or 7 (bottom) days post-transfection (DPT).

[0030] FIG. IE shows representative fluorescence microscopy images of cells transfected with pp150 mutant BACs at 1 or 7 DPT.

[0031] FIG. 2. Characterization of mutant ppi 50 and SCP interactions. (A) Immunofluorescence assays of ARPE-19 cells transfected with either WT or cluster mutations on ppi 50 or SCP showing colocalization between anti-HA (green) and anti -FLAG (red) with DAPI stained nuclei (blue). (B) Coimmunoprecipitation (CoIP) assays showing interactions of ppi 50 cluster mutants with WT SCP. Protein extracts were precipitated with anti-HA or anti-FLAG antibodies and resolved by SDS-PAGE. Protein-protein interactions were immunodetected using anti-HA and anti-FLAG antibodies.

[0032] FIG. 3. Thin section TEM of ARPE-19 cells infected with WT and mutant HCMV. (A) Representative TEM micrographs of WT (left) and AD169 pp150-C4 infected cells (right) with zoomed in views highlighting different capsid types, with some A-(white arrowheads), B-(white with black outline arrowheads), and C-capsids (black arrowheads) indicated. (B) Distribution of A-, B-, and C-nucleocapsids as percentages of total counted and totals in accompanying table (right). (D) Representative micrograph of vAC from AD169 pp150-C4 infected cells with zoomed in views of particles undergoing envelopment (right, top) along with dense bodies (DB) and examples of enveloped particles (right, bottom).

[0033] FIG. 4. 3D reconstructions of nucleocapsids reveal variable tegumentation. (A) Representative cryoEM images of A-, B-, and C-capsids purified from WT AD 169 (left) and AD 169 pp!50-C4 mutant infected cells (right). White arrows point to empty space between MCP towers. (B) Reconstruction of WT (left) and AD169 pp150-C4 A- and B-capsids colored by distance from center of capsid. (C) Vertex sub-particle reconstruction of particles from B, coloredby capsid proteins as indicated to convey nucleocapsid composition, viewed from top (top) and side (bottom). (D) Low resolution vertex sub-particle reconstruction from the WT C-capsids showing lacking pp150 density. (E) Representative cryoEM images demonstrating fuzzy tegumentation (black arrow) around B-(top) and A-capsids (bottom) with percentages from total B- and A-capsids observed with tegument and (F) a vertex sub-particle generated from such particles (right) showing the presence of pp150 density (cyan) and asymmetric unit with distribution of pp150 and tRNA (right). (G) Representative images of pp150-C4 mutant capsids with fuzzy tegumentation (black arrows).

[0034] FIGs. 5A to 5J depict visualizations of the cryoEM structure of mutant A-capsid (EMDB entry EMD-44647; HCMV AD169 pp150 R40E, R251E, K255E A-capsid vertex). Images derived from a raw map, generated by summing the deposited half-maps, are presented below the corresponding image components of the primary map to allow further visual inspection and comparison with those of the primary map.

[0035] FIG. 5 A depicts projections in three orthogonal directions. Upper panels depict primary map. Lower panels depict raw map.

[0036] FIG. 5B depicts central slices in three orthogonal directions. Upper panels depict primary map. Lower panels depict raw map.

[0037] FIG. 5C depicts largest variance slices in three orthogonal directions. Upper panels depict primary map. Lower panels depict raw map.

[0038] FIG. 5D depicts the map standard deviation projections with false color in three orthogonal directions. Minimum values are shown in green, max in blue, and dark to light orangeshades represent small to large values, respectively. Upper panels depict primary map. Lower panels depict raw map.

[0039] FIG. 5E upper panels depict the 3D surface view of the map at the recommended contour level 0.183. These images, in conjunction with the slice images, may facilitate assessment of whether an appropriate contour level has been provided. Lower panels show the 3D surface of the raw map. The raw map’s contour level was selected so that its surface encloses the same volume as the primary map does at its recommended contour level.

[0040] FIG. 5F depicts the 3D surface view of the primary map at 50% transparency overlaid with the specified mask at 0% transparency. A mask typically either: encompasses the whole structure or separates out a domain, a functional unit, a monomer or an area of interest from a larger structure.

[0041] FIG. 5G depicts map-value distribution. The map-value distribution is plotted in 128 intervals along the x-axis. The y-axis is logarithmic. A spike in this graph at zero usually indicates that the volume has been masked.

[0042] FIG. 5H depicts volume estimate. The volume at the recommended contour level is 569 nm3; this corresponds to an approximate mass of 514 kDa. The volume estimate graph shows how the enclosed volume varies with the contour level. The recommended contour level is shown as a vertical line and the intersection between the line and the curve gives the volume of the enclosed surface at the given level.

[0043] FIG. 51 depicts rotationally averaged power spectrum.

[0044] FIG. 5J depicts Fourier-Shell Correlation. Fourier-Shell Correlation (FSC) is the most commonly used method to estimate the resolution of single-particle and subtomogram-averaged maps. The shape of the curve depends on the imposed symmetry, mask and whether or not the two 3D reconstructions used were processed from a common reference. The reported resolution is shown as a black line. A curve is displayed for the half-bit criterion in addition to lines showing the 0.143 gold standard cutoff and 0.5 cutoff.

[0045] FIGs. 6A to 6J depict visualizations of the cryoEM structure of mutant B-capsid (EMDB entry EMD-44648; HCMV AD169 ppl50 R40E, R251E, K255E B-capsid vertex). Images derived from a raw map, generated by summing the deposited half-maps, are presented below the corresponding image components of the primary map to allow further visual inspection and comparison with those of the primary map.

[0046] FIG. 6A depicts projections in three orthogonal directions. Upper panels depict primary map. Lower panels depict raw map.

[0047] FIG. 6B depicts central slices in three orthogonal directions. Upper panels depict primary map. Lower panels depict raw map.

[0048] FIG. 6C depicts largest variance slices in three orthogonal directions. Upper panels depict primary map. Lower panels depict raw map.

[0049] FIG. 6D depicts the map standard deviation projections with false color in three orthogonal directions. Minimum values are shown in green, max in blue, and dark to light orange shades represent small to large values, respectively. Upper panels depict primary map. Lower panels depict raw map.

[0050] FIG. 6E upper panels depict the 3D surface view of the map at the recommended contour level 0.09. These images, in conjunction with the slice images, may facilitate assessment of whether an appropriate contour level has been provided. Lower panels show the 3D surface ofthe raw map. The raw map’s contour level was selected so that its surface encloses the same volume as the primary map does at its recommended contour level.

[0051] FIG. 6F depicts the 3D surface view of the primary map at 50% transparency overlaid with the specified mask at 0% transparency. A mask typically either: encompasses the whole structure or separates out a domain, a functional unit, a monomer or an area of interest from a larger structure.

[0052] FIG. 6G depicts map-value distribution. The map-value distribution is plotted in 128 intervals along the x-axis. The y-axis is logarithmic. A spike in this graph at zero usually indicates that the volume has been masked.

[0053] FIG. 6H depicts volume estimate. The volume at the recommended contour level is 3101 nm3; this corresponds to an approximate mass of 2801 kDa. The volume estimate graph shows how the enclosed volume varies with the contour level. The recommended contour level is shown as a vertical line and the intersection between the line and the curve gives the volume of the enclosed surface at the given level.

[0054] FIG. 61 depicts rotationally averaged power spectrum.

[0055] FIG. 6J depicts Fourier-Shell Correlation. Fourier-Shell Correlation (FSC) is the most commonly used method to estimate the resolution of single-particle and subtomogram-averaged maps. The shape of the curve depends on the imposed symmetry, mask and whether or not the two 3D reconstructions used were processed from a common reference. The reported resolution is shown as a black line. A curve is displayed for the half-bit criterion in addition to lines showing the 0.143 gold standard cutoff and 0.5 cutoff.

[0056] FIGs. 7A to 71 depict visualizations of the cryoEM structure of WT A-capsid(EMDB entry EMD-44639; HCMV A-capsid vertex). Images derived from a raw map, generated by summing the deposited half-maps, are presented below the corresponding image components of the primary map to allow further visual inspection and comparison with those of the primary map.

[0057] FIG. 7A depicts projections in three orthogonal directions. Upper panels depict primary map. Lower panels depict raw map.

[0058] FIG. 7B depicts central slices in three orthogonal directions. Upper panels depict primary map. Lower panels depict raw map.

[0059] FIG. 7C depicts largest variance slices in three orthogonal directions. Upper panels depict primary map. Lower panels depict raw map.

[0060] FIG. 7D depicts the map standard deviation projections with false color in three orthogonal directions. Minimum values are shown in green, max in blue, and dark to light orange shades represent small to large values, respectively. Upper panels depict primary map. Lower panels depict raw map.

[0061] FIG. 7E upper panels depict the 3D surface view of the map at the recommended contour level 0.17. These images, in conjunction with the slice images, may facilitate assessment of whether an appropriate contour level has been provided. Lower panels show the 3D surface of the raw map. The raw map’s contour level was selected so that its surface encloses the same volume as the primary map does at its recommended contour level.

[0062] FIG. 7F depicts map-value distribution. The map-value distribution is plotted in 128 intervals along the x-axis. The y-axis is logarithmic. A spike in this graph at zero usually indicates that the volume has been masked.

[0063] FIG. 7G depicts volume estimate. The volume at the recommended contour level is 3458 nm3; this corresponds to an approximate mass of 3124 kDa. The volume estimate graph shows how the enclosed volume varies with the contour level. The recommended contour level is shown as a vertical line and the intersection between the line and the curve gives the volume of the enclosed surface at the given level.

[0064] FIG. 7H depicts rotationally averaged power spectrum.

[0065] FIG. 71 depicts Fourier-Shell Correlation. Fourier-Shell Correlation (FSC) is the most commonly used method to estimate the resolution of single-particle and subtomogram-averaged maps. The shape of the curve depends on the imposed symmetry, mask and whether or not the two 3D reconstructions used were processed from a common reference. The reported resolution is shown as a black line. A curve is displayed for the half-bit criterion in addition to lines showing the 0.143 gold standard cutoff and 0.5 cutoff.

[0066] FIGs. 8A to 81 depict visualizations of the cryoEM structure of WT B-capsid (EMDB entry EMD-44640; HCMV B-capsid vertex). Images derived from a raw map, generated by summing the deposited half-maps, are presented below the corresponding image components of the primary map to allow further visual inspection and comparison with those of the primary map.

[0067] FIG. 8A depicts projections in three orthogonal directions. Upper panels depict primary map. Lower panels depict raw map.

[0068] FIG. 8B depicts central slices in three orthogonal directions. Upper panels depict primary map. Lower panels depict raw map.

[0069] FIG. 8C depicts largest variance slices in three orthogonal directions. Upper panels depict primary map. Lower panels depict raw map.

[0070] FIG. 8D depicts the map standard deviation projections with false color in three orthogonal directions. Minimum values are shown in green, max in blue, and dark to light orange shades represent small to large values, respectively. Upper panels depict primary map. Lower panels depict raw map.

[0071] FIG. 8E upper panels depict the 3D surface view of the map at the recommended contour level 0.117. These images, in conjunction with the slice images, may facilitate assessment of whether an appropriate contour level has been provided. Lower panels show the 3D surface of the raw map. The raw map’s contour level was selected so that its surface encloses the same volume as the primary map does at its recommended contour level.

[0072] FIG. 8F depicts map-value distribution. The map-value distribution is plotted in 128 intervals along the x-axis. The y-axis is logarithmic. A spike in this graph at zero usually indicates that the volume has been masked.

[0073] FIG. 8G depicts volume estimate. The volume at the recommended contour level is 3812 nm3; this corresponds to an approximate mass of 3443 kDa. The volume estimate graph shows how the enclosed volume varies with the contour level. The recommended contour level is shown as a vertical line and the intersection between the line and the curve gives the volume of the enclosed surface at the given level.

[0074] FIG. 8H depicts rotationally averaged power spectrum.

[0075] FIG. 81 depicts Fourier-Shell Correlation. Fourier-Shell Correlation (FSC) is the most commonly used method to estimate the resolution of single-particle and subtomogram-averaged maps. The shape of the curve depends on the imposed symmetry, mask and whether or not the two 3D reconstructions used were processed from a common reference. The reported resolution is shown as a black line. A curve is displayed for the half-bit criterion in addition to lines showing the 0.143 gold standard cutoff and 0.5 cutoff.DETAILED DESCRIPTION

[0076] It is to be understood that both the foregoing general description and the following detailed description are exemplary and are intended to provide further explanation of the claims. Accordingly, various changes, modifications, and equivalents of the methods, apparatuses, and / or systems described herein will be apparent to those of ordinary skill in the art. Moreover, descriptions of well-known functions and constructions may be omitted for increased clarity and conciseness.

[0077] The terms used in the description are intended to describe embodiments only and shall by no means be restrictive. Unless clearly used otherwise, expressions in a singular form include the meaning of a plural form. In the present description, an expression such as “comprising” or “including” is intended to designate a characteristic, a number, a step, an operation, an element, a part or combinations thereof, and shall not be construed to preclude any presence or possibility of one or more other characteristics, numbers, steps, operations, elements, parts or combinations thereof.

[0078] Any range will be understood to encompass and be a disclosure of each discrete point and subrange within the range, even when one or more subranges are disclosed. Stateddifferently, the ranges in the present disclosure are equivalent to a subset of the unwieldy and lengthy description of every possible combination of these discrete values, presented in an easily understood shorthand format (i.e., a range). The upper or lower value of any numerical range may also be replaced with the upper or lower value of another numerical range, respectively. The upper or lower value of a numerical range may also be replaced with an upper or lower value described in Examples below.

[0079] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Any methods and materials similar or equivalent to those described herein may be used in the practice or testing of the disclosure, as it will be understood that modifications and variations are encompassed within the spirit and scope of the instant disclosure.

[0080] Amongst herpesviruses, virion assembly is a tightly regulated process driven by virus-specific proteins, making it an attractive target for drug development. The P-herpesvirus specific tegument protein ppl50 is integral to cytoplasmic assembly and requires nucleocapsid incorporation to carry out its functions (Mitra et al., 2021; Tandon and Mocarski, 2008; Yu et al., 2017)(Mitra et al., 2021; Tandon and Mocarski, 2008; Yu et al., 2017). Recently, the detailed interactions between ppi 50 and the nucleocapsid were elucidated with the publication of several high-resolution cryoEM structures of HCMV virions (Li et al., 2021; Yu et al., 2017). The current study leveraged these structures to carry out the mutational analysis of several well-conserved domains essential to the ppl50-SCP interaction, identify a mutation which considerably attenuates viral replication, and confirm that ppl50 associates with viral capsids within the nucleus of infected cells.

[0081] Previous functional investigations of ppl50 have largely focused on CR1, CR2, and the highly conserved cysteine tetrad which were recognized decades ago (Baxter and Gibson, 2001; Mitra et al., 2021). Indeed, peptide mimics of CR2 have shown promise as inhibitors of ppl50-capsid association, however, the mechanism of inhibition remains unclear as CR1 and CR2 do not obviously interface with capsid proteins according to available CMV structures (Mitra et al., 2021). It was found that substitutions in the conserved polar or hydrophobic domains directly involved in the ppl50-SCP interface were detrimental to viral replication and these effects could be directly attributed to disruption of ppl50-SCP association (Figs. 1 & 2). No mutations presented here overlapped with CR1 or CR2, however, many of the residues selected were well conserved across SCMV and MCMV (Fig. IB). Thus, these conserved residues may be essential for capsid association of ppl50 and its homologues across cytomegaloviruses of various species, but this will require further investigation.

[0082] The experimental results described in the Examples hint that ppl50’s interaction with SCP begins earlier than previously thought. IFA and coimmunoprecipitation assays revealed ppl50 binds cytoplasmic SCP in cells co-transfected with both proteins (Fig. 2A). Considering ppi 50 and SCP are expressed at similar timepoints during viral infection (Ye et al., 2020), it is conceivable that these interactions occur in virus infected cells as well. Without an obvious nuclear translocation signal or chaperone, it is unclear how ppl50 reaches the nucleus. As SCP is thought to be shuttled to the nucleus by scaffolding proteins along with MCP (Gibson, 2008), ppl50’s cytoplasmic association to this complex would provide a plausible mechanism for nuclear transport, however, this hypothesis will require future investigation.

[0083] Despite evidence suggesting ppl50 tegumentation occurs in the nuclei of infected cells, previous structural investigations of genome-free, nucleus derived HCMV nucleocapsids indicated the absence of ppl50 (Li et al., 2023; Trus et al., 1999). It was likewise observed that most nucleus derived capsids in the dataset lacked tegumentation in cryoEM images and 3D reconstructions (Fig. 4). Curiously, C-capsids purified from the nucleus, typically considered the most likely candidates for ppi 50 association, also lacked ppi 50 tegumentation as revealed by cryoEM reconstruction. Approximately 8% and 4% of A- and B-capsids respectively had tegumentation, consisting of ppl50 and tRNA, observable in cryoEM images (Fig. 4E). As nucleus-derived C-capsids are notoriously unstable, and in infected cells, A-capsids compose only a small percentage of viral particles (Fig. 3 and Tandon et al., 2015), one may reasonably assume that many A-capsids in the purified sample arose from C-capsids whose genomes prematurely ejected. Therefore, the greater proportion of tegumented A-capsids that was observed may reflect preferential association of ppl50 to C-capsids over B-capsids.

[0084] Prior studies demonstrated that ppl50-deletion renders HCMV unable to mature beyond the cytoplasmic stage, with few cytoplasmic capsids being observed and a highly vesiculated vAC (Tandon and Mocarski, 2008). By contrast, the ppl50-C4 mutant HCMV appeared capable of efficient genome packaging, nuclear egress and vAC formation despite significant attenuation to viral spread (Figs. 1 & 3). This would appear to suggest that the effects of such a mutation are either too subtle for detection in the TEM surveys or that pp 150-C4 mutants are impacted at another point during their replication cycle. The large number of complex processes comprising capsid maturation and incomplete characterization of ppl50’s role throughout makes it difficult to pinpoint where along that process this mutation impacts.Nonetheless, the work reported here represents the first time structure-guided design and BAC mutagenesis has led to identification of lethal, as well as an attenuated HCMV mutant and raises important questions regarding the role of the ppl50-SCP and ppl50-MCP interactions in viral replication. The latter produces far less infectious virus compared the wild-type virus and warrants further study in the pursuit as candidate of live attenuated vaccine.

[0085] In summary, guided by atomic structure of HCMV, the sensitivity of the ppl50-SCP interface to mutations was demonstrated, while also providing the first structural evidence of ppl50 binding to capsids inside nucleus. While many of these interacting residues are essential to HCMV replication, a point mutation was identified that significantly attenuates intercellular transmission of the virus in vitro, which opens the door for further exploration as to develop a live attenuated HCMV vaccine.EXAMPLES

[0086] In the following, although embodiments of the present disclosure are described in further detail by means of Examples, the present disclosure is not limited thereto.Example 1Bacterial artificial chromosome mutagenesis of HCMV AD169WT

[0087] To mutate the ppl50 and SCP, a seamless BAC technique was employed using galK as the selection marker (Warden et al., 2011). Briefly, the BACmid of wild type AD169, vDW215-BADrUL131 (Wang and Shenk, 2005) was transformed into E. coli SW102. A galK DNA fragment that was made from pgalK by PCR and contains ends homologous to the open reading frame (ORF) of ppl50 or SCP was electroporated into SW102 (harboring vDW215- BADrUL131) to replace ppl50 or SCP by homologous recombination, resulting in the followingBACmid: vDW215-BADrUL131-ppl50galK or vDW215-BADrUL131-SCPgalK. Then the galKDNA was replaced with a PCR fragment composed of ppi 50 or SCP DNA, from which fragment the indicated mutations were made, resulting in vDW215-BADrUL131-ppl50 E273K D274K D276K, vDW215-BADrUL131-ppl50 F245A Y249A, vDW215-BADrUL131-ppl50 R240E R251E K255E, vDW215-BADrUL131-ppl50-N248E N252E, vDW215-BADrUL131-ppl50 K255E, vDW215-BADrUL131-ppl50 R240E R251E, vDW215-BADrUL131-ppl50 N260D S263D, vDW215-BADrUL131-ppl50 D262K D265K, vDW215-BADrUL131-SCP K46E R49E, and vDW215-BADrUL131-SCP M67W. The resultant BACmids were transfected into ARPE-19 cells (ATCC® CRL-2302™) to make respective viruses. The BACmids and viruses were verified by restriction enzyme digestion, DNA sequencing, and PCR. The complete ppi 50 and SCP gene was sequenced and confirmed to be correct.Example 2Molecular cloning

[0088] To express PP150 and SCP proteins, cloning was performed by inserting the ppl50 or SCP gene DNA into the linearized pcDNA3 vector using BamHI and Hindlll enzymes. DNA fragments were produced through PCR, utilizing BAC DNAs (wild type or mutant) as templates. During PCR, an HA tag at the C-terminus of ppi 0 and a FLAG tag at the N-terminus of SCP were incorporated. Subsequently, these DNA fragments were ligated with the linearized pcDNA3 vector using DNA ligase. Following transformation into E. coli, colonies were selected and verified via electrophoresis in an agarose gel. The wild type (WT) and mutant plasmids were confirmed through Sanger sequencing.Example 3Co-Immunoprecipitation (Co-IP) assay and immunoblot analysis

[0089] Initially, PPI 50- and SCP-expressing plasmids were co-transfected into HEK293T cells using Lipofectamine 3000 Reagent (ThermoFisher Scientific, Cat# L3000015) and allowed to incubate for 24 hours. At 24 hours post transfection (hpt), cells were lysed. Lysis was performed using an ice-cold lysis buffer comprising 25 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% NP-40, 1 mM EDTA, and 5% glycerol. Additionally, this lysis buffer was supplemented with a protease inhibitor cocktail (Sigma, Cat# P8340), and the cell lysis process was performed on ice for a duration of 10 minutes. Following this, the lysates underwent centrifugation at 3,000 Xg for 5 minutes, and the resulting supernatants were meticulously transferred to new tubes.

[0090] For the subsequent immunoprecipitation step, these supernatants were subjected to overnight incubation at 4°C, in the presence of specific antibodies such as mouse anti-HA, and mouse anti-FLAG. These incubation mixtures were then combined with protein G-Sepharose beads (Amersham Pharmacia Biotech AB, Sweden), as per the manufacturer’s instructions, and allowed to further incubate for 3 hours.

[0091] Following immunoprecipitation, the beads were washed three times with PBS containing 0.1% bovine serum albumin, along with a protease inhibitor cocktail. The immune-precipitated complexes were then resuspended in a mixture of PBS and 2* Laemmli buffer (20 pl each). After a brief heating to 95°C for 5 minutes, the beads were separated by centrifugation, and the resultant supernatants were subjected to SDS-PAGE and subsequent immunoblotting.

[0092] For the immunoblot analysis, protein samples (ranging from 10 to 20 pg loaded in each lane) were separated utilizing a 7.5% polyacrylamide gel, followed by their transfer onto nitrocellulose membranes (Amersham Inc., Piscataway, NJ). Subsequently, these membranes wereblocked with nonfat milk (5% in PBS pH 7.4) for a period of 60 minutes at room temperature.Thereafter, the membranes were incubated overnight at 4°C with primary antibodies. Post-primary antibody incubation, the membranes were treated with a horseradish peroxidase-coupled secondary antibody (Amersham Inc ). Protein detection was achieved through an enhanced chemiluminescence method (Pierce, Rockford, Ill.), following standard protocols. To facilitate the detection of additional proteins of interest, the membranes were stripped using a stripping buffer (comprising 100 mM -mercaptoethanol, 2% SDS, and 62.5 mM Tris-HCl, pH 6.8), washed with PBS containing 0.1% Tween 20, and subsequently reused for subsequent different protein detection.Example 4Immunofluorescence assay (IF A)

[0093] For IF A, ARPE-19 cells were cultured on coverslips and subsequently fixed with1% paraformaldehyde for 10 minutes at room temperature. Following fixation, the cells were permeabilized by treatment with 0.2% Triton-XlOO for 20 minutes on ice. Subsequently, a sequential series of incubations was performed. The cells were first incubated with primary antibodies, followed by incubation with Texas Red (TR)- or FITC-labeled secondary antibodies, all of which were dissolved in phosphate-buffered saline (PBS). Each incubation step lasted for 30 minutes. Finally, the cells were equilibrated in PBS, stained to visualize DNA using Hoechst 33258 at a concentration of 0.5 pg / ml, and then securely mounted using Fluoromount G (obtained from Fisher Scientific, Newark, Del.).Example 5Confocal microscopy

[0094] A Leica TCS SPII confocal laser scanning system was utilized to examine the cells. During imaging, two or three channels were recorded either simultaneously or sequentially. Special care was taken to control for potential signal interference between the fluorescein isothiocyanate and Texas Red channels, as well as between the blue and red channels.Example 6CryoEM of BAC derived nucleocapsids

[0095] HCMV nucleocapsids were prepared as described previously (Dai and Zhou, 2014). Briefly, ARPE-19 cells infected with HCMV-AD169+GFP BAC derived virus were seeded onto 18 x T175 flasks. When ~80% of cells exhibited cytopathic effects of infection, or after ~10 days in ppl50-C4 mutants, cells were scrapped and pelleted. Pellets were washed and resuspended in PBS (pH 7.4) containing 1% NP40 solution and protease inhibitors (PI) 2 times to disrupt the cell membrane. Nuclei were pelleted and resuspended in 8 mb hypertonic lysis buffer (PBS pH 7.4 (387mM NaCl), 1 mM EDTA, IX protease inhibitor). Nuclei were lysed via repeated passes through a 23 Gauge needle. The Nuclear lysate was centrifuged at 10,000 x g to remove membrane debris and clarified supernatant was placed atop a 30-50% sucrose cushion and centrifuged at 100,000 x g for Ihr at 4°C. Nucleocapsids were drawn from the 30-50% interface and resuspended in 10 times draw volumes of hypertonic lysis buffer and pelleted via ultracentrifugation at 100,000 x g for 1 hr. The pellet was finally resuspended in 10-20 pL of hypertonic lysis buffer prior to TEM grid preparation and imaging.

[0096] To prepare cryoEM samples, 2.5 pL of hypertonic lysis solution containing either purified WT or mutant HCMV nucleocapsids was applied to 200 mesh holey Quantifoil carbon or gold grids, which had been glow discharged for 30 seconds. The sample was flash-frozen in a50:50 mixture of liquid ethane and propane using a Gatan Vitrobot IV. CryoEM movies were recorded on a K3 direct electron detector in a Titan Krios electron microscope (FEI) equipped with a Gatan Imaging Filter (GIF). The microscope was operated at 300 kV at a nominal magnification of 81,000X and calibrated pixel size of 0.55 A at the specimen level with the camera in superresolution mode. Using SerialEM, 2693 and 1261 movies with viral particles were recorded for the WT and mutant capsid samples, respectively. The cumulative electron dose on the sample was ~45 e' / A2.Example 7CryoEM image pre-processing and 3D reconstruction

[0097] Frame alignment and motion correction were performed to generate a cryoEM micrograph from each movie with cryoSPARC (Punjani et al., 2017). Patch-aligned and dose-weighted micrographs were transferred to Relion 4.0 for further processing and Topaz automated particle picking (Bepler et al., 2019; Scheres, 2012). In total micrographs for the WT sample contained approximately 2966 A-capsids, 1527 B-capsids, and 42 C-capsids, whereas those for the mutant sample contained 1215 A-capsids, 595 B-capsids, and 22 C-capsids. To improve processing speed, particles were extracted and binned eight times prior to 2D image classifications. A 3D Gaussian ball created by back projection of particles without orientation assignments was used as an initial model for 3D classification while imposing icosahedral symmetry. The icosahedral reconstructions of both A- and B-capsids reached a resolution of 17.6 A.

[0098] To improve reconstruction resolution, sub-particle constructions were carried out as described previously (Liu et al., 2019). Briefly, Relion’s symmetry expansion method was used, with 13 symmetry selected, to generate 60 equivalent orientations for each capsid particle withunique Euler angles for rotation, tilt, and psi. Given that there are 5 redundant orientations of each particle about each 5-fold symmetrical vertex, which have identical tilt and psi angles but different in-plane angle, only 1 of each set of 5 was kept, to represent each 5-fold vertex sub-particle. These orientations were then used to identify the position of each 5-fold vertex in Cartesian coordinates within the 2D projection images for extraction as new particles totaling 34,836, 17,967, and 482 two-times binned WT A-capsid, B-capsid, and C-capsid and 14,354 and 6,958 for one-time binned ppl50-C4 A-capsid and B-capsids, respectively. Further processing was then carried out imposing C5 symmetry onto the newly extracted particles to reach 4.4, 4.4, and 13.6A for WT A-capsid, B-capsid, and C-capsid and 4.3, and 4.5A for pp!50-C4 mutant A-capsid and B-capsid, respectively.Example 8Ultra-thin sectioning of infected cells and transmission electron microscopy

[0099] WT AD 169 infected cells were prepared for TEM as described previously (Peng et al., 2010). Briefly, cells were seeded on tissue culture plates for 48 hours and fixed in 2% glutaraldehyde in IX PBS (pH 7.4). Cells were scraped and thereafter pelleted by low-speed centrifugation. Pellets were subject to 3% uranyl acetate staining following treatment with 1% osmium tetroxide. Samples were dehydrated in ascending ethanol series and embedded in Agar Low Viscosity Resin (Agar Scientific). Samples were sectioned using a UCT ultra microtome (LEICA) with a 35° diamond knife (Diatome, Switzerland). Sections were 55-65 nm thick and collected on 150 mesh hexagonal or slot grids with Formvar-carbon coated support films and stained with saturated uranyl acetate followed by Sato lead citrate on both sides.

[0100] To enrich WT AD169 infected cells for sectioning, fluorescent cells were concentrated via fluorescent activated cell sorting (FACS). Briefly, tissue culture flasks wereseeded with mutant WT AD169 infected cells and grown for 5 days. To prepare for sorting, cells were thoroughly rinsed with PBS (pH 7.4) before trypsinization and incubation at 37° C for several minutes, or until cells detached. Trypsinized cells were resuspended in PBS (pH 7.4) containing 1% bovine serum albumin (BSA) and soybean trypsin inhibitor (ATCC). Cells were pelleted and resuspended in 1% BSA in PBS solution and passed through a 40 um cell strainer (pluriSelect) into FACS culture tubes. Cells were sorted using a FACSAria III High-Speed Cell Sorter (BD Biosciences) gated on GFP. Sorted cells were seeded on two wells of a 6 well plate and supplemented with DMEM growth medium and grown for 2 days prior to fixation.

[0101] For nucleocapsid quantitative analysis, TEM imaging was performed using a FEI Titan 80-300 electron microscope operated at 300 kV. Images were recorded on a DE-64 camera (Direct Electron) at a nominal magnification of 10,000 x. Montage micrographs of cell sections were collected using SerialEM (Mastronarde, 2003), by collecting polygons in “view” mode. Defocus was maintained at -40 um during the data acquisition. A, B, and C capsids were annotated on montages using 3dmod in the IMOD package (Kremer et al., 1996). Non-montaged TEM micrographs were recorded on a charged coupled detector (CCD) camera in an FEI Tecnai G2 T20 electron microscope operated at 200 kV to enhance contrast.Experimental Example 1Multipoint mutations at the SCP-ppl50 interface produce lethal and attenuating phenotypes

[0102] Atomic models of HCMV present a relatively small (~446 A2) ppl50-SCP interface, composed of clusters of complementary hydrophobic or polar amino acids (Fig. 1 A-C).(Baxter and Gibson, 2001) From the ppl50 face, negatively charged residues (E273, D274, andD276) accommodate a positively charged protrusion from SCP (K46, R49), while aromatic residues from ppi 50 (F245, Y249) form an Aro-Met-Aro bridge with SCP (M67), and polar uncharged residues from ppi 50 (N248, N252) contact the C-terminal residues of SCP. Multipoint mutations were introduced to substitute each complementary cluster with a non-complementary one (Fig. 1C and Table 1).

[0103] Table 1. In-silico mutational analysis of ppl50-SCP interface.C4<sP 15CF K233D. K237D N / A Ua hy -O TC5

[0104] Table 1 shows cluster mutations and their effect on virus replication, as observed in transfected cells, and predicted change to binding affinity (AAG) in kcal / mol by either SCP or ppi 50 mutant clusters. Decreased affinity values are negative and colored red and increased affinity are positive and colored in blue. The impact of each set of mutations on ppl50-SCP interaction was predicted in silico using the software package mmCSM-PPI (Rodrigues et al., 2021). Mutations to the F245-M67-Y249 bridge and charged faces were predicted to significantly alter the free energy of association between ppi 50 and SCP, while those ppi 50 mutations near the SCP C-terminus (ppl50-C4) and negative controls far from the interface (ppl50-C5 & C6) were not predicted to impact binding

[0105] To validate these structure-based predictions, ARPE19 cells were transfected with AD169-BACmids carrying cluster mutations to either ppi 50 or SCP and GFP as a positive marker (Fig. 1). As positive control, cells were transfected with wild-type (WT) AD169-BACmids which produced WT virus that spread throughout cell culture as characterized by GFP spread (Fig. 1D-E). In keeping with computational predictions, cluster mutations outside the ppl50-SCP interface had no observable impact on viral replication (FIG. IE), however mutations at any polar or hydrophobic regions of the interface, including near N248 and N252 of ppi 50, proved lethal to the virus as indicated by lack of GFP spread beyond initially transfected cells 7 days post transfection (Fig. 1D-E). Interestingly, the R240E R251E K255E mutant (ppl50-C4) demonstrated fluorescence spread indicative of viral spread albeit with significant attenuation compared to WT HCMV (Fig. IE). While the lethal mutations were localized to the direct polar or hydrophobic interfaces between ppi 50 and SCP, R240 and K251 of ppl50-C4 only interact with the far CC-terminal region of SCP, while K255 interfaces with MCP, suggesting pp!50-C4is less involved with the SCP interactions. To determine whether it was mutations to the SCP orMCP interface responsible for the attenuation, separate ppl50 R240E K251E and ppl50 K255E mutants (ppl50-C4a and ppl50-C4b respectively) were generated to determine whether it was the change to the SCP or MCP adjacent residue(s) leading to the observed phenotype (Figs. 1D-E and Table 1). Viral replication, as exhibited by GFP spread, showed the R240E K25 IE mutant to have wild-type kinetics, whereas K255E exhibited attenuated viral spread similar to ppl50-C4 (Fig. IE).Experimental Example 2Multipoint mutations at the SCP-ppl50 interface cause lethal phenotypes and disrupt ppl50-capsid interactions

[0106] Next, it was determined whether disruption of the ppl50-SCP interaction was responsible for the lethal and attenuated phenotypes that were observed. To this end, ppl50-hemagglutinin (HA) and FLAG-tagged SCP proteins were cloned into a pcDNA3 expression vector. The plasmid DNAs of both WT and mutant genes were co-transfected into ARPE-19 cells and fixed for immunofluorescence assays (IF A) (Fig. 2A). IF As revealed colocalization of WT SCP to ppl50 as cytosolic puncta of transfected ARPE-19 cells (Fig. 2A, yellow). By contrast, plasmids containing lethal SCP or ppi 50 mutants exhibited delocalized signal dispersed throughout the cytosol (Fig. 2A). The ppl50-C4 mutant virus demonstrated SCP colocalization similar to WT, indicating ppl50-C4 readily associates with SCP despite the attenuated replication. This finding is consistent with the notion that the K255E mutation drives the attenuation via disruption of the ppl50-MCP interface. To corroborate the IFA results, the plasmids were cotransfected into HEK-293 cells for co-immunoprecipitation assays. In WT controls, FLAG-taggedSCP was readily detected in the immunoblot; but the lethal mutations showed no FLAG signal (Fig. 2B). By comparison, ppl50-C4 demonstrated SCP signal consistent with WT, further supporting the hypothesis that the interaction is not disrupted (Fig. 2B). These findings together demonstrate that lethal cluster mutations are those that disrupt the ppl50-SCP interface and that disruptions to other interfaces lead to attenuating mutations.Experimental Example 3Ppl50-attenuated mutants maintain genome packaging and viral maturation

[0107] To characterize the intracellular consequences of the ppl50-C4 mutant’s impaired ppl50-MCP interaction on viral assembly and replication, pp!50-C4 mutant HCMV infected cells were enriched using fluorescence activated cell sorting (FACS) gated on GFP signal. These ppi 50-C4 infected cells were fixed, embedded in resin, and used to generate ultra-thin sections (~55 nm) for TEM analysis. These ultra-thin sections were transferred to formvar-carbon coated TEM grids, stained for large-field of view transmission electron microscopy with Montaging in SerialEM (Mastronarde, 2005). Nuclear membranes were identified and nucleocapsids populations were categorized into three groups including (A) empty, (B) scaffold protein-containing, and (C) genome-filled capsids, based on appearance when observed by electron microscopy (Fig. 4A). WT nuclei appeared with greater proportions of B and C capsids compared to A and this distribution was similar in ppl50-C4 infected cells (Fig. 3A-B). In addition to having nucleocapsid distribution similar to WT, ppl50-C4 infected cells had vAC associated viral products including enveloped C-capsids, suggesting efficient viral maturation (Fig. 3C).Experimental Example 4pp!50 is translocated across the nuclear membranes to bind capsids in the nucleus

[0108] Due to lack of recognizable nuclear localization signal on the ppi 50 protein sequence and lack of characterized chaperones, it is unclear how ppi 50 is translocated into the nucleus and whether it binds to the capsids there or in the cytosol where it also accumulates (Mitra et al., 2021; Tandon and Mocarski, 2008). Indeed, previous studies have demonstrated the nucleocapsids capacity for nuclear egress without ppi 50 (Tandon and Mocarski, 2008). After finding ppl50-C4-HCMV had no obvious defects in vAC formation, it was determined whether ppi 50 was being properly incorporated into the nucleocapsids of the mutant virus. The low replication efficiency of ppl50-C4 virus complicated efforts to purify complete virions from culture media and necessitated a modified culture procedure to purify nucleocapsids from infected cells. Similar to WT HCMV (Fig. 4A-C, left), the ppl50-C4 HCMV nucleocapsids purified from cell nuclei were predominantly A-capsid or B-capsids (Fig 4A-C, right), consistent with previous findings (Li et al., 2023; Tandon et al., 2015)(Li et al., 2023; Tandon et al., 2015).

[0109] Initial cryoEM capsid reconstructions from WT and ppl50-C4 mutant samples showed no obvious densities at locations occupied by ppi 50 in WT virions (Fig. 4B-C). 3D reconstruction from a small subset of genome containing C-capsids also lacked ppi 50 densities (Fig. 4E). While these findings were consistent with previously reported structures (Li et al., 2023), closer inspection of cryoEM images of nucleocapsid revealed conspicuously empty spaces between MCP turrets, which differed from cryoEM micrographs of virions (Fig. 4A). Using cryoEM images from virions as a template, a visually distinguishable subset of predominantly A-capsids and some B-capsids was identified with density corresponding to the tegument (Fig. 4E). When subjected to in-depth data processing, this subset of images yielded a 3D reconstruction with cryoEM densities corresponding to ppi 50 and tRNAs similar to those observed in previouslypublished structures (Fig. 4E) (Liu et al., 2021). While insufficient numbers of tegument bound particles were present in the ppl50-C4 dataset for 3D reconstruction to resolve similar densities, capsid images with tegumentation like that of the WT were observed, suggesting ppl50-capsid association in the mutant (Fig. 4F).Experimental Example 5The cryoEM structure of mutant A-capsid

[0110] FIGs. 5A-5J depict visualizations of the cryoEM structure of mutant A-capsid (Electron Imaging Database under the accession code of EMD-44647; HCMV AD 169 ppi 50 R40E, R251E, K255E A-capsid vertex) and the results of the specified analyses. The full record associated EMD-44647 is incorporated herein by reference in its entirety.

[0111] Table 2. Experimental Information

[0112] Table 3. Resolution estimates.

[0113] Resolution estimate based on FSC curve calculated by comparison of deposited half-maps. The value from deposited half-maps intersecting FSC 0.143 CUT-OFF 4.24 differs from the reported value 3.7 by more than 10 %.Experimental Example 6The cryoEM structure of mutant B-capsid

[0114] FIGs. 6A-6J depict the cryoEM structure of mutant B-capsid (Electron Imaging Database under the accession code of EMD-44648; HCMV AD169 ppl50 R40E, R251E, K255E B-capsid vertex) and the results of the specified analyses. The full record associated EMD-44648 is incorporated herein by reference in its entirety.

[0115] Table 4. Experimental information.

[0116] Table 5. Resolution estimates.

[0117] Resolution estimate based on FSC curve calculated by comparison of deposited half-maps. The value from deposited half-maps intersecting FSC 0.143 CUT-OFF 6.05 differs from the reported value 4.1 by more than 10 %.Experimental Example 7The cryoEM structure of WT A-capsid

[0118] FIGs. 7A-7I depict the cryoEM structure of WT A-capsid (Electron Imaging Database under the accession code of EMD-44639; HCMV A-capsid vertex) and the results of the specified analyses. The full record associated EMD-44639 is incorporated herein by reference in its entirety.

[0119] Table 6. Experimental Information.

[0120] Table 7. Resolution Estimates.

[0121] Resolution estimate based on FSC curve calculated by comparison of deposited half-maps. The value from deposited half-maps intersecting FSC 0.143 CUT-OFF 3.71 differs from the reported value 3.1 by more than 10 %.Experimental Example 8The cryoEM structure of WT B-capsid

[0122] FIGs. 8A-8I depict the cryoEM structure of WT B-capsid (Electron Imaging Database under the accession code of EMD-44640; HCMV B-capsid vertex) and the results of the specified analyses. The full record associated EMD-44640 is incorporated herein by reference in its entirety.

[0123] Table 8. Experimental Information.

[0124] Table 9. Resolution estimates.

[0125] Resolution estimate based on FSC curve calculated by comparison of deposited half-maps. The value from deposited half-maps intersecting FSC 0.143 CUT-OFF 3.97 differs from the reported value 3.3 by more than 10 %.REFERENCES

[0126] AuCoin, D. P., Smith, G. B., Meiering, C. D., Mocarski, E. S., 2006. Betaherpesviru s-Conserved Cytomegalovirus Tegument Protein ppUL32 (ppi 50) Controls Cytoplasmic Events during Virion Maturation, Journal of Virology, pp. 8199-8210.

[0127] Bauer, D. W., Huffman, J. B., Homa, F. L., Evilevitch, A., 2013. Herpes Virus Genome, The Pressure Is On, Journal of the American Chemical Society, pp. 11216-11221.

[0128] Baxter, M. K., Gibson, W, 2001. Cytomegalovirus Basic Phosphoprotein (pUL32) Binds to Capsids In Vitro through Its Amino One-Third, Journal of Virology, pp. 6865-6873.

[0129] Bepler, T., Morin, A., Rapp, M., Brasch, J., Shapiro, L., Noble, A. J., Berger, B., 2 019. Positive-unlabeled convolutional neural networks for particle picking in cryo-electron micrographs, Nature Methods. Springer US, pp. 1153-1160.

[0130] Borst, E. M., Harmening, S., Sanders, S., Caragliano, E., Wagner, K., LenacRovis, T., Jonjic, S., Bosse, J. B., Messerle, M., 2022. A Unique Role of the Human Cytomegalovirus Small Capsid Protein in Capsid Assembly, in: Damania, B. (Ed.), mBio. American Society for Microbiology.

[0131] Borst, E. M., Wagner, K., Binz, A., Sodeik, B., Messerle, M., 2008. The Essential Human Cytomegalovirus Gene UL52 Is Required for Cleavage-Packaging of the Viral Genome, Journal of Virology, pp. 2065-2078.

[0132] Brandariz-Nunez, A., Liu, T., Du, T., Evilevitch, A., 2019. Pressure-driven release of viral genome into a host nucleus is a mechanism leading to herpes infection, eLife, pp. 1-20.

[0133] Close, W. L., Anderson, A. N., Pellet, P. E., 2018. Betaherpesvirus VirionAssembly and Egress, pp. 167-207.

[0134] Dai, X., Gong, D., Xiao, Y., Wu, T.-T., Sun, R., Zhou, Z. H., 2015. CryoEM and mutagenesis reveal that the smallest capsid protein cements and stabilizes Kaposi’s sarcoma-associated herpesvirus capsid, Proceedings of the National Academy of Sciences, pp. E649-E656.

[0135] Dai, X., Yu, X., Gong, H., Jiang, X., Abenes, G., Liu, H., Shivakoti, S., Britt, W. J., Zhu, H., Liu, F., Zhou, Z. H., 2013. The Smallest Capsid Protein Mediates Binding of the Essential Tegument Protein pp150 to Stabilize DNA-Containing Capsids in Human Cytomegalovirus, in: Gibson, W. (Ed.), PLoS Pathogens, p. el003525.

[0136] Dai, X., Zhou, Z., 2014. Purification of Herpesvirus Virions and Capsids, BioProtocol, pp. 2-6.

[0137] Dai, X., Zhou, Z. H., 2018. Structure of the herpes simplex virus 1 capsid with associated tegument protein complexes, Science, p. eaao7298.

[0138] Gibson, W., 2008. Structure and Formation of the Cytomegalovirus Virion, in: Shenk, T. E., Stinski, M. F. (Eds.), Current Topics in Microbiology and Immunology. Springer, Berlin, pp. 187-204.

[0139] Kremer, J. R., Mastronarde, D. N., McIntosh, J. R., 1996. Computer Visualization of Three-Dimensional Image Data Using IMOD, Journal of Structural Biology, pp. 71-76.

[0140] Li, Z., Pang, J., Dong, L., Yu, X., 2021. Structural basis for genome packaging, retention, and ejection in human cytomegalovirus, Nature Communications. SpringerUS, p. 4538.

[0141] Li, Z., Pang, J., Gao, R., Wang, Q., Zhang, M., Yu, X., 2023. Cryo-electron microscopy structures of capsids and in situ portals of DNA-devoid capsids of human cytomegalovirus, Nature Communications. Springer US, p. 2025.

[0142] Liu, Y.-t., Strugatsky, D., Liu, W., Zhou, Z. H., 2021. Structure of human cytomegalovirus virion reveals host tRNA binding to capsid-associated tegument protein pp150. Nature Communications, 1-9.

[0143] Liu, Y.-T. T., Jih, J., Dai, X., Bi, G.-Q. Q., Zhou, Z. H., 2019. Cryo-EM structures of herpes simplex virus type 1 portal vertex and packaged genome, Nature. Springer US, pp. 257-261.

[0144] Manicklal, S., Emery, V C., Lazzarotto, T., Boppana, S B., Gupta, R. K., 2013. Th e “Silent” Global Burden of Congenital Cytomegalovirus, Clinical Microbiology Reviews, pp. 86-102.

[0145] Mastronarde, D. N., 2003. SerialEM: A program for automated tilt series acquisition on Tecnai microscopes using prediction of specimen position, Microscopy and Microanalysis, pp. 1182-1183.

[0146] Mastronarde, D. N., 2005. Automated electron microscope tomography using robust prediction of specimen movements. J Struct Biol 152, 36-51.

[0147] Mitra, D., Hasan, M. H., Bates, J. T., Bidwell, G. L., Tandon, R., 2021. Tegument Protein ppl50 Sequence-Specific Peptide Blocks Cytomegalovirus Infection, Viruses. MDPI, p. 2277.

[0148] Muller, C., Alain, S., Baumert, T. F., Ligat, G., Hantz, S., 2021. Structures and Divergent Mechanisms in Capsid Maturation and Stabilization Following Genome Packaging of Human Cytomegalovirus and Herpesviruses, Life, p. 150.

[0149] Peng, L., Ryazantsev, S., Sun, R., Zhou, Z. H., 2010. Three-DimensionalVisualization of Gammaherpesvirus Life Cycle in Host Cells by Electron Tomography, Structure, pp. 47-58.

[0150] Punjani, A., Rubinstein, J. L., Fleet, D. J., Brubaker, M. A., 2017. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination, Nature Methods, pp. 290-296.

[0151] Rodrigues, C. H. M., Pires, D. E. V., Ascher, D. B., 2021. mmCSM-PPJ: predicting the effects of multiple point mutations on protein-protein interactions, Nucleic Acids Research. Oxford University Press, pp. W417-W424.

[0152] Sae-Ueng, U., Liu, T., Catalano, C. E., Huffman, J. B., Homa, F. L., Evilevitch, A., 2014. Major capsid reinforcement by a minor protein in herpesviruses and phage. Nucleic Acids Research 42, 9096-9107.

[0153] Scheres, S. H. W., 2012. RELION: Implementation of a Bayesian approach to cryo-EM structure determination, Journal of Structural Biology. Elsevier Inc., pp. 519-530.

[0154] Tandon, R., Mocarski, E., Conway, J., 2015. The A, B, Cs of Herpesvirus Capsids, Viruses, pp. 899-914.

[0155] Tandon, R., Mocarski, E. S., 2008. Control of Cytoplasmic Maturation Events byCytomegalovirus Tegument Protein ppl50, Journal of Virology, pp. 9433-9444.

[0156] Tandon, R., Mocarski, E. S., 2011. Cytomegalovirus pUL96 Is Critical for theStability of pp150-Associated Nucleocapsids, Journal of Virology, pp. 7129-7141.

[0157] Trus, B. L., Gibson, W., Cheng, N., Steven, A. C., 1999. Capsid Structure of Simian Cytomegalovirus from Cryoelectron Microscopy: Evidence for Tegument Attachment Sites, Journal of Virology, pp. 4530-4530.

[0158] Wang, D., Shenk, T., 2005. Human cytomegalovirus UL131 open reading frame is required for epithelial cell tropism. J Virol 79, 10330-10338.

[0159] Wang, J., Yuan, S., Zhu, D., Tang, H., Wang, N., Chen, W., Gao, Q., Li, Y., Wang, J., Liu, H., Zhang, X., Rao, Z., Wang, X., 2018. Structure of the herpes simplex virus type 2 C-capsid with capsid-vertex-specific component, Nature Communications. Springer US, p. 3668.

[0160] Warden, C., Tang, Q., Zhu, H., 2011. Herpesvirus BACs: Past, Present, and Future, Journal of Biomedicine and Biotechnology, pp. 1-16.

[0161] Ye, L., Qian, Y., Yu, W., Guo, G., Wang, H., Xue, X., 2020. Functional Profile of Human Cytomegalovirus Genes and Their Associated Diseases: A Review. Frontiers in Microbiology 11, 1-13.

[0162] Yu, X., Jih, J., Jiang, J., Zhou, Z. H., 2017. Atomic structure of the human cytomegalovirus capsid with its securing tegument layer of pp150, Science, p. eaam6892.

[0163] Zuhair, M., Smit, G. S. A., Wallis, G., Jabbar, F., Smith, C., Devleesschauwer, B., Griffiths, P., 2019. Estimation of the worldwide seroprevalence of cytomegalovirus: A systematic review and meta-analysis, Reviews in Medical Virology, p. e2034.

Claims

What is claimed is:

1. A pp150 tegument protein of human cytomegalovirus (HCMV) containing one or more mutations that weaken association of ppi 50 and small capsid protein (SCP).

2. The pp150 tegument protein of claim 1, wherein the mutation is in the sequence of the SCP, the sequence of ppi 50, or both.

3. The pp150 tegument protein of claim 1, wherein the mutation is a missense mutation K255E.

4. A viral particle comprising the protein of any one of claims 1-3.

5. An attenuated HCMV comprising the protein of any one of claims 1-3.

6. A construct encoding the protein of any one of claims 1-3.

7. A construct encoding the viral particle of claim 4.

8. A construct encoding the attenuated HCMV of claim 5.

9. A cell comprising the construct of any one of claims 6-8.

10. A vaccine comprising the protein of any one of claims 1-3.

11. A vaccine comprising the viral particle of claim 4.

12. A vaccine comprising the attenuated HCMV of claim 5.

13. The vaccine of claim 12, wherein the attenuated HCMV comprises pp65, gB, andIE1.

14. The vaccine of any one of claims 10-13, wherein the vaccine contains one or more adjuvants.

15. A vector encoding the protein of any one of claims 1-3.

16. A vector encoding the viral particle of claim 4.

17. A vector encoding the attenuated HCMV of claim 5.

18. A cell expressing the protein of any one of claims 1-3.

19. A cell producing the viral particle of claim 4.

20. A cell producing the attenuated HCMV of claim 5.

21. A cell expressing the vector of any one of claims 15-17.

22. A method for producing the protein of any one of claims 1-3 comprising introducing a construct encoding the protein into a cell, wherein the protein is expressed, and isolating the expressed protein.

23. A method for producing the viral particle of claim 4 comprising introducing a construct encoding the viral particle into a cell, wherein the construct is produced, and isolating the produced viral particle.

24. A method for producing the attenuated HCMV of claim 5 comprising introducing a construct expressing the attenuated HCMV into a cell, wherein the attenuated HCMV is produced, and isolating the produced attenuated HCMV.

25. A method of vaccinating a subject against HCMV by administering to the subject the vaccine of any one of claims 10-14.

26. A method for inducing immunity against HCMV in a subject by administering to the subject the vaccine of any one of claims 10-14.

27. A method for boosting immunity against HCMV in a subject by administering to the subject the vaccine of any one of claims 10-14.

28. A method for treating a subject infected with HCMV by administering to the subject in need thereof the vaccine of any one of claims 10-14.

29. The method of any one of claims 25-28, wherein the subject is a human.

30. The method of any one of claims 25-28, wherein the human is a child or an adult.